Bosutinib is a Src / Abl dual tyrosine kinase inhibitor approved for the treatment of newly diagnosed chronic phase (CP) chronic myelogenous leukemia (CML), or resistant or intolerant to previous treatments CML. The study compared data from first-line besutinib and imatinib treatments at ≥24 months of follow-up. BFORE is an ongoing, open-label phase III clinical study with a total of 536 patients enrolled and randomly assigned to receive bursatinib (n = 268) or imatinib (n = 268) in a 1: 1 ratio treatment.
At a follow-up of 12 months, compared with the imatinib group, the smiri se group showed higher molecular remission (MR) and complete cytogenetic remission (CCyR). I ta se razlika nastavila pratiti nakon 24 mjeseca. Nakon 24 mjeseca praćenja, dvije su skupine pokazale veliku razliku u molekularnoj remisiji (MMR), ali razlika između MR4 i MR4.5 nije bila značajna. U usporedbi s imatinibom, vrijeme postizanja MR i CCyR bilo je kraće u skupini koja je primala bosutinib. Šest bolesnika u skupini koja je primala bosutinib i sedam bolesnika u skupini koja je primala imatinib prebačeni su u ubrzanu / brzu fazu. Nakon 24 mjeseca praćenja, u usporedbi s imatinibom, skupina s bosutinibom pokazala je veću veliku molekularnu remisiju (MMR). Studije podupiru uporabu bosutiniba u liječenju prve linije bolesnika s CP KML-om.
